CARLSBAD, Calif. and LA JOLLA, Calif., June 9 /PRNewswire/ -- The Immune
Response Corporation (Nasdaq: IMNR) and Agouron Pharmaceuticals, Inc. today
announced that they have been informed by the AIDS Clinical Trials Group
(ACTG) that enrollment in the 96 week, randomized, double-blind, adjuvant-
controlled study, previously announced on May 10, 2000, has been halted while
it reviews protocol changes. The 131 participants already enrolled in the
study will continue to be followed under the current version until a new
protocol can be developed. The study protocol team has also informed The
Immune Response Corporation and Agouron Pharmaceuticals, Inc. that the revised
study protocol is expected to be developed quickly.
The ACTG noted that REMUNE remains a safe way of inducing large helper
T cell responses to HIV antigens. The study was designed to answer the
scientific question of whether vaccine-induced immune responses could aid in
the control of HIV, and the practical question of whether this intervention
could prolong the efficacy of potent antiretroviral therapy.
REMUNE is under study in several other clinical trials, including pivotal
registration trials in the U.S., Europe and the recently completed trial in
Thailand. In addition, the National Institutes of Health is currently
sponsoring other trials of REMUNE in adults and children.
For more information on REMUNE clinical trials, dial toll-free
1-877-858-7783.
Agouron Pharmaceuticals, Inc., a wholly owned subsidiary of the Warner-
Lambert Company (NYSE: WLA), is an integrated pharmaceutical company committed
to the discovery, development, manufacturing, and marketing of innovative
therapeutic products engineered to inactivate proteins that play key roles in
cancer, AIDS, and other serious diseases. Agouron employs more than 1200
people of whom approximately 800 are engaged in research and development.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy that is designed to enable the intravenous injection of genes
for delivery to the liver.
The ACTG is a multicenter cooperative clinical trials group funded by the
Division of AIDS, National Institute of Allergy and Infectious Diseases of the
National Institutes of Health. It is involved in various phases of clinical
research, from early safety studies to large-scale efficacy trials. It
evaluates new drugs and drug combinations for the treatment of HIV infection
in adults.
NOTE: News releases for The Immune Response Corporation are available
through PR Newswire Company News On-Call fax service. For a menu of available
news releases or to retrieve a specific release made by The Immune Response
Corporation, please call 800-758-5804, extension 434675. Please retain these
numbers for future reference. Company information can also be located on the
Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether additional clinical trials will be
successfully concluded and whether REMUNE will be approved for marketing or be
successfully commercialized. Those factors are discussed more thoroughly in
The Immune Response Corporation's SEC filings, including but not limited to
its report on Form 10-K for the year ended December 31, 1999 and subsequent
forms 10-Q. The Company undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements which may be made
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
REMUNE(TM) is a trademark of The Immune Response Corporation.
Agouron(R) is a registered trademark of Agouron Pharmaceuticals, Inc.
SOURCE Immune Response Corporation; Agouron Pharmaceuticals,
Inc.
 back to top
Related links:
http://www.imnr.com
CONTACT:
Kathy Lane of The Immune Response
Corporation, 760-771-2236; or Joy Schmitt of Agouron
Pharmaceuticals, Inc., 858-622-3220
|
